Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Acute Coronary Syndrome Overview | 8 | 1 |
| Therapeutics Development | 9 | 1 |
| Pipeline Products for Acute Coronary Syndrome Overview | 9 | 1 |
| Acute Coronary Syndrome Therapeutics under Development by Companies | 10 | 1 |
| Acute Coronary Syndrome Pipeline Products Glance | 11 | 3 |
| Late Stage Products | 11 | 1 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Acute Coronary Syndrome Products under Development by Companies | 14 | 1 |
| Acute Coronary Syndrome Companies Involved in Therapeutics Development | 15 | 17 |
| advanceCor GmbH | 15 | 1 |
| Arena Pharmaceuticals, Inc. | 16 | 1 |
| Ascendia Pharmaceuticals LLC | 17 | 1 |
| Athera Biotechnologies AB | 18 | 1 |
| Bayer AG | 19 | 1 |
| Cardiome Pharma Corp. | 20 | 1 |
| Cerenis Therapeutics Holding SA | 21 | 1 |
| CSL Limited | 22 | 1 |
| Esperion Therapeutics, Inc. | 23 | 1 |
| HitGen LTD | 24 | 1 |
| Japan Tobacco Inc. | 25 | 1 |
| Lee's Pharmaceutical Holdings Limited | 26 | 1 |
| LipimetiX Development Inc | 27 | 1 |
| MedImmune LLC | 28 | 1 |
| Pfizer Inc. | 29 | 1 |
| The Medicines Company | 30 | 1 |
| Verseon Corporation | 31 | 1 |
| Acute Coronary Syndrome Therapeutics Assessment | 32 | 9 |
| Assessment by Monotherapy Products | 32 | 1 |
| Assessment by Target | 33 | 2 |
| Assessment by Mechanism of Action | 35 | 2 |
| Assessment by Route of Administration | 37 | 2 |
| Assessment by Molecule Type | 39 | 2 |
| Drug Profiles | 41 | 49 |
| 4-WF Drug Profile | 41 | 1 |
| AEM-28 Drug Profile | 42 | 2 |
| AEM-2802 Drug Profile | 44 | 1 |
| Biologics for Acute Coronary Syndrome Drug Profile | 45 | 1 |
| CER-001 Drug Profile | 46 | 4 |
| clopidogrel bisulphate Drug Profile | 50 | 1 |
| COR-2 Drug Profile | 51 | 1 |
| CSL-112 Drug Profile | 52 | 2 |
| dalcetrapib Drug Profile | 54 | 4 |
| MDCO-216 Drug Profile | 58 | 3 |
| MEDI-6012 Drug Profile | 61 | 2 |
| PC-mAb Drug Profile | 63 | 2 |
| PF-06282999 Drug Profile | 65 | 1 |
| PMC-6 Drug Profile | 66 | 1 |
| PR-15 Drug Profile | 67 | 2 |
| rivaroxaban Drug Profile | 69 | 14 |
| Small Molecules to Inhibit PCSK9 for Acute Coronary Syndrome and Atherosclerosis Drug Profile | 83 | 1 |
| Small Molecules to Inhibit Thrombin for Cardiovascular Diseases Drug Profile | 84 | 1 |
| temanogrel hydrochloride Drug Profile | 85 | 2 |
| tirofiban hydrochloride Drug Profile | 87 | 1 |
| ZK-001 Drug Profile | 88 | 2 |
| Acute Coronary Syndrome Dormant Projects | 90 | 2 |
| Acute Coronary Syndrome Discontinued Products | 92 | 2 |
| Acute Coronary Syndrome Product Development Milestones | 94 | 14 |
| Featured News &Press Releases | 94 | 1 |
| Sep 01, 2016: FDA Approves New AGGRASTAT Product Format | 94 | 1 |
| Aug 30, 2016: Completion of patient enrolment in the CARAT study meeting the clinical schedule | 94 | 1 |
| Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial | 95 | 1 |
| Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics | 96 | 1 |
| Jul 07, 2016: Medicure Receives Response Letter from FDA on AGGRASTAT sNDA for New Indication | 97 | 1 |
| May 11, 2016: Medicure Files Application for New AGGRASTAT Product Format | 98 | 1 |
| Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial | 98 | 1 |
| Apr 25, 2016: Patent Term for Rivaroxaban Extended in US | 99 | 2 |
| Dec 14, 2015: The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published in European Heart Journal- Cardiovascular Pharmacotherapy | 101 | 2 |
| Nov 10, 2015: Cerenis Therapeutics: New Data for CER-001 Presented in Key Oral Session at American Heart Association Conference 2015 | 103 | 1 |
| Sep 08, 2015: First patients enter phase II CARAT trial to assess reduction in atherosclerotic plaque using CER-001 in post Acute Coronary Syndrome (ACS) patients | 103 | 1 |
| Jul 23, 2015: Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides | 104 | 1 |
| Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery | 105 | 1 |
| May 11, 2015: Xarelto Bleeding Lawsuit Judge Orders the Selection of Cases for Discovery, Reports Xarelto Lawsuit Funding Firm, Fair Rate Funding | 106 | 2 |
| Appendix | 108 | 2 |
| Methodology | 108 | 1 |
| Coverage | 108 | 1 |
| Secondary Research | 108 | 1 |
| Primary Research | 108 | 1 |
| Expert Panel Validation | 108 | 1 |
| Contact Us | 108 | 1 |
| Disclaimer | 109 | 1 |